TY - JOUR T1 - Endothelial dysfunction determines severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks JF - medRxiv DO - 10.1101/2021.07.08.21260169 SP - 2021.07.08.21260169 AU - Louisa Ruhl AU - Isabell Pink AU - Jenny F. Kühne AU - Kerstin Beushausen AU - Jana Keil AU - Stella Christoph AU - Andrea Sauer AU - Lennart Boblitz AU - Julius Schmidt AU - Sascha David AU - Hans-Martin Jäck AU - Edith Roth AU - Markus Cornberg AU - Thomas F. Schulz AU - Tobias Welte AU - Marius M. Höper AU - Christine S. Falk Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/10/2021.07.08.21260169.abstract N2 - The systemic processes involved in the manifestation of life-threatening COVID-19 and in disease recovery are still incompletely understood, despite investigations focusing on the dysregulation of immune responses after SARS-CoV-2 infection. To define hallmarks of severe COVID-19 and disease recovery in convalescent patients, we combined analyses of immune cells and cytokine/chemokine networks with endothelial activation and injury. ICU patients displayed an altered immune signature with prolonged lymphopenia but expansion of granulocytes and plasmablasts along with activated and terminally differentiated T and NK cells and high levels of SARS-CoV-2-specific antibodies. Core signature of seven plasma proteins revealed a highly inflammatory microenvironment in addition to endothelial injury in severe COVID-19. Changes within this signature were associated with either disease progression or recovery. In summary, our data suggest that besides a strong inflammatory response, severe COVID-19 is driven by endothelial activation and barrier disruption, whereby recovery depends on the regeneration of the endothelial integrity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the German Research Foundation DFG FA-483/1-1, the German Center for Infection Research DZIF TTU-IICH 07_913 and the Lower Saxony Ministry of Research and Culture (ImProVIT). HMJ is supported by a grant (01KI2043) from the Bundesmininisterium fuer Bildung und Forschung (BMBF), funds from the Bavarian State ministry for Science and the BMBF-funded COVIM project (NaFoUniMedCovid19).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Hannover Medical School Ethics Committee. All patients or participants provided written informed consent before participation in the study (9001 BO K, 968-2011).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this study are available in the main text or the supplementary materials. ER -